This in-depth analysis explores competitive advantages, transformative trends, and key players poised to influence global diagnostics and oncology through 2030. Access the comprehensive market research report here for further insights.
Spotlights on the Industry’s Top Liquid Biopsy Companies
The Liquid Biopsy market is evolving rapidly, guided by advances in next-generation sequencing, automation, and high-sensitivity detection principles.
Also read- 12 Leading Microfluidics Companies
In this dynamic environment, the following industry leaders stand out for their technical innovations, strategic focus, and pivotal roles in clinical diagnostics and research worldwide.
1. Myriad Genetics Inc.
Myriad Genetics Inc. is a leader in genetic testing and precision medicine, offering advanced liquid biopsy solutions that assess hereditary cancer risk and guide treatment decisions. Their robust portfolio integrates germline and tumor data to provide comprehensive insights for clinicians.
Also read- 16 Leading High Potency Active Pharmaceutical Ingredients (HPAPI) Companies
2. Exact Sciences Corporation
Exact Sciences Corporation is renowned for its non-invasive screening and diagnostic capabilities, particularly in the early detection of colorectal cancer. Their continuous innovation in multi-cancer early detection technologies positions them as a dominant force in the market.
3. Biocartis
Biocartis specializes in fully automated molecular diagnostics, offering rapid and easy-to-use platforms for liquid biopsy applications. Their Idylla™ platform enables decentralized testing, making high-precision diagnostics accessible in a variety of hospital and laboratory settings.
Also read- 25 Leading Vaccine Companies
4. Sysmex Corporation
Sysmex Corporation leverages its global leadership in hematology to advance liquid biopsy technologies, focusing on the detection of circulating tumor cells and DNA. Their integrated systems offer high-throughput solutions that enhance laboratory efficiency and diagnostic accuracy.
5. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides a comprehensive suite of liquid biopsy tools, ranging from next-generation sequencing instruments to advanced assay kits. Their solutions enable precise analysis of ctDNA, supporting both clinical research and routine diagnostic workflows.
6. Biocept Inc.
Biocept Inc. is recognized for its proprietary Target Selector™ technology, which enhances the detection of oncogene mutations in blood samples. Their focus on capturing both circulating tumor cells and cell-free DNA ensures high sensitivity for monitoring cancer progression.
7. Agilent Technologies Inc.
Agilent Technologies Inc. delivers robust solutions for nucleic acid analysis, playing a critical role in the liquid biopsy workflow through their automation and enrichment technologies. Their platforms are designed to improve the reliability and speed of genomic profiling from liquid samples.
8. MDxHealth SA
MDxHealth SA focuses on epigenetic information to develop advanced molecular diagnostic tests for urologic cancers. Their liquid biopsy assays provide actionable insights that help physicians identify patients at high risk for prostate and other cancers.
9. NeoGenomics Laboratories
NeoGenomics Laboratories operates a vast network offering comprehensive oncology testing, including extensive liquid biopsy panels. Their service-oriented model ensures that healthcare providers have access to the latest genomic technologies for patient management.
10. F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. combines pharmaceutical expertise with diagnostic innovation to lead in personalized healthcare. Their liquid biopsy solutions, such as the FoundationOne® Liquid CDx, set the standard for comprehensive genomic profiling in oncology.
11. Guardant Health
Guardant Health is a pioneer in the field, known for its Guardant360® platform which has transformed blood-based cancer testing. They focus heavily on data-driven insights to unlock the potential of liquid biopsies for early detection and recurrence monitoring.
12. Bio-Techne
Bio-Techne offers specialized exosome-based diagnostics through its Exosome Diagnostics brand, capturing RNA and DNA from biofluids. Their unique approach allows for the detection of biomarkers that may be missed by cell-free DNA approaches alone.
13. Illumina Inc.
Illumina Inc. provides the foundational sequencing technology that powers a vast majority of liquid biopsy assays globally. Their high-throughput NGS platforms allow for deep sequencing of blood samples, enabling the detection of rare variants with high precision.
14. QIAGEN N.V.
QIAGEN N.V. excels in sample preparation and molecular testing technologies, offering “Sample to Insight” solutions for liquid biopsy. Their PAXgene and circulating nucleic acid kits are industry standards for preserving and isolating high-quality biomarkers.
15. Lucence Health Inc.
Lucence Health Inc. develops ultrasensitive liquid biopsy tests capable of detecting cancer-related mutations with high specificity. Their proprietary technology amplifies the signal of circulating tumor DNA, making it highly effective for early screening.
16. Personal Genome Diagnostics Inc.
Personal Genome Diagnostics Inc. (PGDx) empowers laboratories with decentralized kitted solutions for comprehensive genomic profiling. Their Elio™ plasma focus enables local labs to perform high-quality liquid biopsy testing in-house.
17. SAGA Diagnostics
SAGA Diagnostics utilizes proprietary ultrasensitive technologies like IBSAFE® to detect extremely low frequencies of mutations. Their focus on minimal residual disease monitoring offers critical value for tracking treatment response.
18. Agena Bioscience Inc.
Agena Bioscience Inc. offers the MassARRAY® System, a cost-effective and high-throughput platform for targeted genetic analysis. Their liquid biopsy panels are designed for rapid screening of actionable mutations in clinical research settings.
19. The Menarini Group
The Menarini Group, through its Menarini Silicon Biosystems division, specializes in the isolation and analysis of circulating tumor cells. Their CELLSEARCH® system remains a gold standard for CTC enumeration in metastatic cancer.
20. MiRXES Pte Ltd.
MiRXES Pte Ltd. is a global leader in microRNA detection technology, applying it to the early detection of cancers via blood tests. Their GASTROClear™ test exemplifies the potential of miRNA signatures in liquid biopsy screening.
21. Molecular Health GmbH
Molecular Health GmbH focuses on computational biomedicine, providing software that interprets complex genomic data from liquid biopsies. Their tools help clinicians translate raw sequencing data into actionable therapeutic strategies.
22. EONE-Diagnomics Genome Center (EDGC)
EDGC utilizes cutting-edge genomic analysis to offer liquid biopsy services for cancer screening and prenatal testing. Their cell-free DNA technology is adapted for both early cancer detection and health monitoring.
23. BARD1
BARD1 (now part of INOVIQ) focuses on exosome-based diagnostics and autoantibody detection to identify cancer at early stages. Their multi-marker approach aims to improve the specificity and sensitivity of screening tests.
24. ArcherDX
ArcherDX (part of Invitae) provides anchored multiplex PCR (AMP™) chemistry that excels in detecting fusions and other complex variants in liquid biopsy samples. Their customized panels are widely used for comprehensive tumor profiling.
25. CellMax Life
CellMax Life integrates circulating tumor cell isolation with ctDNA analysis to provide a multi-modal liquid biopsy approach. Their technology is designed to detect pre-cancerous lesions and early-stage cancers with high accuracy.
26. ClearNote Health
ClearNote Health focuses on epigenomic methods to detect early-stage cancers by analyzing DNA methylation patterns. Their non-invasive tests aim to identify cancer signals in patients before standard imaging can detect them.
27. DiaCarta
DiaCarta leverages its Xenonucleic Acid (XNA) molecular clamping technology to highly sensitive detection of rare mutations. Their assays are particularly effective for detecting low-abundance variants in blood plasma.
28. Singlera Genomics
Singlera Genomics specializes in methylation-based liquid biopsy technologies for early cancer detection and diagnosis. Their proprietary platforms enable efficient screening of multiple cancer types from a single blood draw.
29. Sysmex Inostics
Sysmex Inostics, a subsidiary of Sysmex Corporation, provides ultra-sensitive digital PCR and NGS liquid biopsy services. Their OncoBEAM™ and SafeSEQ technologies are widely used in clinical trials for oncology drug development.
30. Helio Genomics
Helio Genomics combines AI-driven analysis with methylation sequencing to improve early cancer detection, particularly for liver cancer. Their HelioLiver test represents a significant advancement in blood-based screening for hepatocellular carcinoma.
31. Natera Inc.
Natera Inc. is a market leader in cell-free DNA testing, known for its personalized Signatera™ MRD test. Their technology tracks tumor-specific mutations to monitor recurrence and treatment response with exceptional sensitivity.
32. Angle plc
Angle plc has developed the Parsortix® system, a unique microfluidic technology for capturing and harvesting circulating tumor cells. This epitope-independent approach allows for downstream analysis of intact cells, providing deeper biological insights.
33. 4D Lifetec
4D Lifetec offers the 4D Lifetest™, a pioneering liquid biopsy assay that detects early cancer through immunotoxicity markers. Their approach focuses on the body’s immune response to early tumor formation.
34. Adela
Adela utilizes a genome-wide methylation enrichment technology to detect cancer and other diseases from a simple blood sample. Their platform is highly efficient, focusing on the most informative regions of the methylome.
35. Alamar Biosciences
Alamar Biosciences develops ultra-sensitive protein analysis technologies that complement genomic liquid biopsies. Their NULISA™ platform enables the detection of low-abundance protein biomarkers in biofluids.
36. Amoy Diagnostics
Amoy Diagnostics provides high-quality molecular diagnostic kits, including panels for detecting EGFR, KRAS, and other mutations in blood. Their products are widely adopted in Asia and Europe for guiding targeted cancer therapies.
37. Aqtual
Aqtual leverages a novel platform that analyzes cell-free DNA fragments and their associated proteins to deduce gene expression. This “proteogenomic” approach offers a distinct layer of information for liquid biopsy analysis.
38. Arna Genomic
Arna Genomic utilizes blockchain and AI to enhance the security and analysis of liquid biopsy data. They are developing decentralized solutions to improve the traceability and integrity of genomic testing.
39. BioCaptiva
BioCaptiva has developed the BioSaptor™, a device that captures cell-free DNA directly from the patient’s blood in vivo. This novel collection method allows for higher yields of ctDNA compared to standard venous blood draws.
40. BioFluidica
BioFluidica enables the isolation of rare biomarkers, including CTCs, exosomes, and cfDNA, using a microfluidic platform. Their technology is designed to process whole blood with high recovery rates for diagnostic applications.
41. BioMark Diagnostics Inc.
BioMark Diagnostics Inc. focuses on metabolomics and liquid biopsy solutions for the early detection of cancers such as lung and glioblastoma. Their assays analyze small molecule metabolites to identify disease signatures.
42. C2i Genomics
C2i Genomics applies whole-genome sequencing and AI pattern recognition to detect minimal residual disease. Their software-as-a-service platform enables labs to perform ultra-sensitive cancer monitoring globally.
43. Delfi Diagnostics Inc.
Delfi Diagnostics Inc. pioneers a fragmentomics approach, analyzing the fragmentation patterns of cell-free DNA to detect cancer. This cost-effective method aims to make high-performance screening accessible to broader populations.
44. Droplet Biosciences
Droplet Biosciences focuses on detecting cancer recurrence through lymph liquid biopsy. Their technology analyzes lymphatic fluid collected after surgery to identify residual tumor cells before they spread systematically.
45. Exai Bio
Exai Bio utilizes RNA-based liquid biopsy technology to detect cancer earlier and more accurately. Their platform analyzes orphan non-coding RNAs in the blood, which provide dynamic insights into tumor biology.
46. Foresight Diagnostics
Foresight Diagnostics develops ultrasensitive liquid biopsy tests for minimal residual disease detection using phased sequencing. Their technology distinguishes tumor DNA from healthy DNA with high precision to guide adjuvant therapy.
47. Genemo
Genemo specializes in RNA-based biomarkers and molecular diagnostics. They focus on developing non-invasive tests that leverage gene expression signatures found in circulating biofluids.
48. Genomill
Genomill offers the Geno1™ technology, an NGS-based method tailored for cost-effective and sensitive liquid biopsy analysis. Their solution targets specific genetic regions to streamline the detection of actionable mutations.
49. Haystack Oncology
Haystack Oncology, acquired by Quest Diagnostics, specializes in highly sensitive ctDNA testing for MRD. Their chemistry is optimized to detect residual disease with high accuracy, aiding in clinical decision-making for solid tumors.
50. Hedera Dx
Hedera Dx provides a streamlined liquid biopsy solution that integrates blood testing with real-world evidence data. Their platform aims to democratize access to simple and effective cancer profiling for community oncologists.
51. Hummingbird Diagnostics
Hummingbird Diagnostics analyzes the immune system’s response to disease by sequencing small RNAs in blood. Their miRNA-based platform offers early detection capabilities for lung cancer and other pathologies.
52. IMBdx
IMBdx offers a comprehensive liquid biopsy platform, AlphaLiquid®, which detects genetic mutations across a wide panel of cancer genes. They are a leading player in the Asian market, providing essential genomic profiling services.
53. IVBH Bio
IVBH Bio develops liquid biopsy technologies that focus on isolation and characterization of circulating tumor cells. Their systems are designed to support personalized medicine by providing viable cells for downstream drug testing.
54. JaxBio
JaxBio utilizes advanced DNA methylation detection technologies for early cancer screening. Their “one-step” detection methods aim to simplify the liquid biopsy workflow while maintaining high sensitivity.
55. MetaSight Diagnostics
MetaSight Diagnostics combines mass spectrometry and metabolic profiling to detect early-stage diseases from blood samples. Their approach offers a cost-effective alternative to traditional genomic liquid biopsies.
56. MiCareo
MiCareo has developed a microfluidic system for the rare cell isolation and analysis, targeting CTCs and immune cells. Their technology enables single-cell characterization to better understand tumor heterogeneity.
57. Mirnax Biosens
Mirnax Biosens focuses on electrochemical biosensors for the detection of circulating microRNAs. Their point-of-care technology aims to bring liquid biopsy testing out of the central lab and closer to the patient.
58. MiRoncol
MiRoncol utilizes a multi-biomarker approach, combining protein and DNA markers, to enhance the accuracy of cancer screening. Their tests are designed to be affordable and scalable for population health applications.
59. Nucleix
Nucleix specializes in epigenetics and methylation analysis, with tests like Bladder EpiCheck® designed for urine-based recurrence monitoring. Their highly sensitive chemistry allows for non-invasive detection in fluids other than plasma.
60. OncoDxRx
OncoDxRx offers a broad range of liquid biopsy services, including analysis of ctDNA, CTCs, and exosomes. Their integrated “pan-omic” approach provides a holistic view of the patient’s cancer status.
61. Oxford Cancer Analytics
Oxford Cancer Analytics uses machine learning and proteomics to detect early-stage cancers from blood samples. Their “CaPP-Seq” inspired approaches focus on maximizing signal-to-noise ratios for reliable screening.
62. Pillar Biosciences
Pillar Biosciences develops SLIMamp® technology, a streamlined library preparation method for NGS that works well with low-input liquid biopsy samples. Their kitted solutions allow local labs to perform rapid and accurate ctDNA testing.
63. Precipio Diagnostics
Precipio Diagnostics focuses on preventing misdiagnosis through its specialized pathology and liquid biopsy services. Their HemeScreen™ technology simplifies molecular testing for hematologic malignancies.
64. Foundation Medicine
Foundation Medicine, a subsidiary of Roche, offers FoundationOne® Liquid CDx, a comprehensive pan-cancer liquid biopsy test. It is widely used for genomic profiling to match patients with approved targeted therapies and immunotherapies.
65. SmartCatch
SmartCatch develops intravascular devices to capture circulating tumor cells directly from the blood flow. This innovative “fishing” technique overcomes the volume limitations of standard blood draws.
66. Predicine
Predicine offers a comprehensive genomic profiling platform using urine and blood-based liquid biopsies. Their technology is particularly noted for its utility in urological cancers and non-invasive monitoring.
67. Johnson & Johnson
Johnson & Johnson employs liquid biopsy technologies primarily through its Janssen pharmaceutical division to support clinical trials and drug development. They focus on companion diagnostics that identify patients suitable for their targeted oncology portfolio.
68. Laboratory Corporation of America Holdings
LabCorp is a global life sciences company that provides widespread access to liquid biopsy testing through its vast reference laboratory network. They offer both proprietary tests and partnered solutions to support routine clinical care.
69. Merck (MSD)
Merck (MSD) invests heavily in liquid biopsy research to support the development of its oncology pipeline, including Keytruda. They utilize biomarker analysis to identify responders to immunotherapy and monitor long-term outcomes.
70. Vortex Biosciences Inc.
Vortex Biosciences Inc. utilizes microfluidic technology to isolate label-free circulating tumor cells based on their physical properties. Their VTX-1 platform delivers intact CTCs suitable for downstream molecular analysis.
71. Exosome Diagnostics Inc.
Exosome Diagnostics Inc. (a Bio-Techne brand) is a leader in developing biofluid-based tests that analyze exosomal RNA. Their ExoDx™ Prostate test helps physicians determine the need for a prostate biopsy.
72. MedGenome Inc.
MedGenome Inc. provides genomic solutions with a focus on South Asian populations, offering liquid biopsy services for cancer management. Their “OncoTrack” liquid biopsy test monitors ctDNA to assess treatment efficacy.
73. Epigenomics AG
Epigenomics AG is a molecular diagnostics company focused on blood-based DNA methylation tests. Their Epi proColon® test is the first FDA-approved blood test for colorectal cancer screening.
74. Grail
Grail is transforming cancer care with its Galleri® test, a multi-cancer early detection liquid biopsy that screens for over 50 types of cancer. Their methylation-based technology is designed to detect cancer signals before symptoms appear.
75. Bio-Rad Laboratories Inc.
Bio-Rad Laboratories Inc. provides Droplet Digital PCR (ddPCR) systems which are the gold standard for absolute quantification of nucleic acids in liquid biopsy. Their technology is essential for the ultra-sensitive detection of rare mutations in blood.
Conclusion: Unlock the Full Liquid Biopsy Market Intelligence
The Liquid Biopsy market’s future is shaped by a blend of technological convergence, regulatory evolution, and strategic adaptation among its leading companies.
To explore in-depth trends, segmentation insights, and actionable recommendations for sustainable growth, access the full Leading Liquid Biopsy Companies Shaping Innovation and Market Growth to 2030 report now.